Ranbaxy gets USFDA's tentative approval for Galantamine tablets

New Delhi, Aug 30 (UNI) Ranbaxy Laboratories Limited (RLL) today said it has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market a drug used to treat Alzheimer syndrome.

The drug Galantamine Hydrobromide tablets is used in the treatment of mild to moderate dementia of the Alzheimer's type and its annual market sales were 130 million dollars, company said in a statement.

''The tentative approval will provide us an opportunity to market this product and anticipate sharing in the period of 180 days exclusivity that will be beneficial to the company, as well as to the US healthcare system,'' company's Vice President Sales Jim Meehan said.

Ranbaxy will launch the product upon final approval, which is expected by December next year.

UNI